Correlation Between Viracta Therapeutics and Dowlais Group

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Dowlais Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Dowlais Group into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Dowlais Group plc, you can compare the effects of market volatilities on Viracta Therapeutics and Dowlais Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Dowlais Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Dowlais Group.

Diversification Opportunities for Viracta Therapeutics and Dowlais Group

0.33

Correlation Coefficient

Viracta Therapeutics  Dowlais Group

Weak diversification

The 3 months correlation between Viracta and Dowlais is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Dowlais Group plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dowlais Group plc and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Dowlais Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dowlais Group plc has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Dowlais Group go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Dowlais Group

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Dowlais Group. In addition to that, Viracta Therapeutics is 1.18 times more volatile than Dowlais Group plc. It trades about -0.02 of its total potential returns per unit of risk. Dowlais Group plc is currently generating about -0.01 per unit of volatility. If you would invest  153.00  in Dowlais Group plc on March 12, 2024 and sell it today you would lose (65.00) from holding Dowlais Group plc or give up 42.48% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	54.03%
Values	Daily Returns

Viracta Therapeutics  vs.  Dowlais Group plc

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Dowlais Group plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Dowlais Group plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Pair Trading with Viracta Therapeutics and Dowlais Group

The main advantage of trading using opposite Viracta Therapeutics and Dowlais Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Dowlais Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dowlais Group will offset losses from the drop in Dowlais Group's long position.

The idea behind Viracta Therapeutics and Dowlais Group plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.